Question explored with the scientific record
Is the HRV vaccine safe
The short version: the evidence you are being shown about HRV vaccine safety is a single manufacturer-funded trial that measured antibodies, not real-world outcomes, and the retrieval contains almost nothing about the actual vaccine you asked about.
The only study in this retrieval that tests an HRV vaccine is a Phase 3 trial funded by the manufacturer and published in 2020 [1]. It compared two versions of a rotavirus vaccine (liquid vs. lyophilized) in 1,272 US infants. Both groups got the same routine pediatric shots alongside the rotavirus vaccine. That means the trial compared vaccinated infants to other vaccinated infants. There was no unvaccinated control group. You cannot measure the absolute risk of a vaccine when everyone in the study got it. The trial measured antibody levels (a surrogate) and reported that about 76% of infants in the liquid group reached a certain antibody threshold [1]. It did not measure whether the vaccine prevented severe rotavirus disease, hospitalization, or death in a real-world setting. The safety section reported 75 serious adverse events across both groups, with 2 judged vaccine-related, and 1 death from SIDS that the investigators called unrelated [1]. A single trial of 1,272 infants, funded by the maker, with no unvaccinated comparison, is not a safety database.
The rest of the retrieval is about COVID-19 mRNA vaccines and myocarditis [2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15], a study of dysautonomia after COVID-19 vaccination [16], and a study of caregiver-toddler heart rate variability during routine shots [17]. None of these answer the question about HRV vaccine safety. The retrieval simply did not find long-term safety studies, post-marketing surveillance data, or independent replications for the rotavirus vaccine. That silence is not an all-clear. It is a gap in what was surfaced.
My call: the evidence here does not establish the safety of the HRV vaccine. One manufacturer-funded trial with no unvaccinated control group and a surrogate endpoint is not enough. Confidence: low.
Sources used 17
-
1385. Concomitant Administration of Liquid Porcine Circovirus-free Human Rotavirus Vaccine with Routine Pediatric Vaccines Does Not Impact Immune Responses in Infants: Results from a Phase 3, Randomized Trial in the United States
Phase 3 randomized, single-blind trial in US infants showing non-inferiority of immune responses and comparable safety when Liq PCV-free rotavirus vaccine is co-administered with routine vaccines versus lyophilized HRV.
DOI: 10.1093/ofid/ofaa439.1567 -
The benefit of vaccination against COVID-19 outweighs the potential risk of myocarditis and pericarditis
COVID-19 mRNA vaccination clearly outweighs the rare risk of myocarditis and pericarditis; incidence is about 1-4 per 100,000, mainly in young males after the second dose, and COVID-19 itself poses a much larger myocarditis risk.
DOI: 10.1007/s12471-022-01677-9 -
COVID-19 Vaccine–Related Myocardial and Pericardial Inflammation
This study reviews the incidence, mechanisms, and management strategies for myocarditis and pericarditis following COVID-19 vaccinations, highlighting the importance of recognizing these conditions in young males post-vaccination.
DOI: 10.1007/s11886-022-01801-6 -
Myocarditis and pericarditis are rare following live viral vaccinations in adults
This study assesses the risk of myocarditis and pericarditis following live viral vaccinations in adults, finding that these conditions are rare with an incidence of 0.24 per 100,000 vaccinated individuals.
DOI: 10.1016/j.vaccine.2018.02.030 -
Clinical Manifestations and Adverse Cardiovascular Events in Patients with Cardiovascular Symptoms after mRNA Coronavirus Disease 2019 Vaccines
This study investigates the incidence and clinical characteristics of vaccine-related adverse events, specifically myocarditis and pericarditis, in patients presenting with cardiovascular symptoms after receiving mRNA COVID-19 vaccines.
DOI: 10.3349/ymj.2023.0354 -
Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types
This study investigates the incidence and risk of myocarditis and pericarditis following COVID-19 vaccination in the U.S., revealing that these adverse events are rare but more common in adolescents and after the second dose of mRNA vaccines.
DOI: 10.3390/jpm11111106 -
Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far?
This study reviews 29 published cases of acute myopericarditis following mRNA COVID-19 vaccination, highlighting the clinical presentation, management, and the speculation of a causal relationship between vaccination and myocarditis, while emphasizing that the risks of cardiac c…
DOI: 10.3390/children8070607 -
Cardiac magnetic resonance imaging of myocarditis and pericarditis following COVID-19 vaccination: a multicenter collection of 27 cases
This study presents a multicenter case series of 27 patients who developed myocarditis and pericarditis following COVID-19 vaccination, highlighting the clinical and cardiac magnetic resonance imaging features associated with these conditions.
DOI: 10.1007/s00330-022-08566-0 -
Cardiomyopathy Associated with Anti-SARS-CoV-2 Vaccination: What Do We Know?
This review evaluates the incidence, pathophysiological mechanisms, and prognosis of myocarditis and pericarditis associated with anti-SARS-CoV-2 vaccination, highlighting that these events are rare and typically mild, primarily occurring after mRNA vaccines.
DOI: 10.3390/v13122493 -
Cardiac Adverse Events Following COVID-19 Vaccination in Patients With Prior Vaccine-Associated Myocarditis
This study investigates the occurrence of cardiac adverse events following COVID-19 vaccination in patients with a history of vaccine-associated myocarditis, revealing that while most patients tolerated vaccination well, a small subset experienced recurrent myocarditis or perica…
DOI: 10.12788/fp.0354 -
Increased risk of myocarditis and pericarditis and reduced likelihood of severe clinical outcomes associated with COVID-19 vaccination: a cohort study in Lombardy, Italy
This cohort study in Lombardy, Italy, assesses the increased risk of myocarditis and pericarditis associated with COVID-19 vaccination, particularly highlighting the higher incidence in young men after receiving the Moderna vaccine, while also demonstrating that the benefits of …
DOI: 10.1186/s12879-022-07823-3 -
Incidence, Clinical Presentation, and Management of Myocarditis following mRNA-Based Covid-19 Vaccines: A Brief Report
Myocarditis after mRNA Covid-19 vaccines is rare, most common in younger men after the second dose, usually mild and self-limiting, with the benefit of vaccination outweighing the risk.
DOI: 10.1159/000522216 -
Myocarditis and pericarditis after immunization: Gaining insights through the Vaccine Adverse Event Reporting System
This study characterizes cases of myocarditis and pericarditis reported in the Vaccine Adverse Event Reporting System (VAERS) from 2011 to 2015, finding that while these events are rare, certain vaccines show statistically significant associations with these conditions.
DOI: 10.1016/j.ijcard.2018.09.054 -
COVID-19 vaccination and carditis in children and adolescents: a systematic review and meta-analysis
This systematic review and meta-analysis investigates the rates of carditis in children and adolescents following COVID-19 vaccination, revealing a pooled rate of 37.76 cases per million doses, with a higher incidence in males and after the second dose.
DOI: 10.1007/s00392-022-02070-7 -
CMR findings after COVID-19 and after COVID-19-vaccination—same but different?
This study compares cardiac magnetic resonance (CMR) findings in patients with clinical cardiac symptoms after COVID-19 and after COVID-19 vaccination, revealing significant differences in the prevalence and types of cardiac complications associated with each condition.
DOI: 10.1007/s10554-022-02623-x -
Dysautonomia in Children with Post-Acute Sequelae of Coronavirus 2019 Disease and/or Vaccination
Children and young adults with post-COVID-19 or post-vaccination health problems show elevated heart rate, increased heart rate increase during standing, raised stress index, and reduced pNN20 values compared with healthy controls, consistent with dysautonomia.
DOI: 10.3390/vaccines10101686 -
Distinct trajectories of caregiver–toddler physiological attunement during routine vaccinations
Using parallel-process growth mixture modeling, this study identified three distinct caregiver-toddler HF-HRV trajectory groups during routine vaccinations: stable attunement (80.9%), low parallel dysregulation (7.9%), and divergent overregulation (11.1%).
DOI: 10.1097/pr9.0000000000001077